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Background: Intratumoral microvessel density (MVD) could be used as a prognostic factor in
colorectal cancer. We retrospectively analyzed the value of microvessel count in predicting the
clinical outcome of stage I and II (Dukes A and B) rectal cancer patients.
Methods: Eighty-four patients who had undergone curative resection of lymph node–negative
rectal cancer were included. Tumor type and differentiation, the depth of local invasion, venous
invasion, the character of the invasive margin, and the degree of lymphocytic infiltration were
evaluated for each tumor specimen. Immunohistochemical staining for the CD31 endothelial antigen
was performed to highlight the microvessels.
Results: The median value of MVD was 45 microvessels. Low MVD (microvessels 45) was
observed in 41 patients (48.8%), and high MVD (45) was found in 43 (51.2%). The presence of
conspicuous lymphocytic infiltration was significantly associated with increased vessel density.
With uni- and multivariate survival analysis MVD did not show any prognostic significance. The
character of the invasive margin was the only parameter with independent prognostic value.
Conclusions: MVD does not seem to provide any additional prognostic information when
compared with standard histopathological parameters in lymph node–negative rectal cancer. It is
likely that the strong association between MVD and the presence of conspicuous lymphocytic
infiltration may interfere with its predictive value.
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Experimental evidence has shown that neoangiogen-
esis is essential for the growth of solid tumors.1,2 It has
also been demonstrated that tumor angiogenesis is a
complex process that depends on the activity of several
angiogenic promoters, such as vascular endothelial
growth factor,3 basic fibroblast growth factor,4 and plate-
let-derived endothelial cell growth factor (PD-ECGF).5 It
has been suggested that intratumoral microvessel density
(MVD) could be used as an indirect parameter of the
prognostic value of angiogenesis: an increase in the
number of tumor vessels is believed to increase the
possibility of tumor cells entering the blood flow, thus
causing metastasis in distant organs.6–8 A relationship
between high MVD and increased risk of tumor recur-
rence and metastasis has been reported in breast can-
cer,9,10 non-small-cell lung carcinoma,11 and melano-
ma.12 The results of a number of investigations on
colorectal cancer have shown that there is a strong cor-
relation between high MVD and the presence of lymph
node or distant metastases.13–16 Very few studies have
addressed the issue of the predictive value of MVD in
lymph node–negative (LNN) colorectal cancer: the re-
sults have not been conclusive.17–19 To our knowledge,
the possible prognostic role of MVD in LNN rectal
cancer has not been reported.
The aim of this retrospective study was to analyze the
value of microvessel count in predicting the clinical
outcome of T2/T3N0M0 (American Joint Committee on
Cancer [AJCC]/International Union Against Cancer
[UICC] stage I and II, Dukes A and B) rectal cancer
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patients. We compared the quantitative assessment of
angiogenesis with other well-known histopathological




Between 1989 and 1996, 170 consecutive patients
underwent radical surgical resection of rectal tumors
(located no farther than 15 cm from the anal verge) at the
Department of General Surgery, University of Florence
(Italy). Eighty-four patients were included in the study:
60 (71.4%) were men, and 24 (28.6%) were women
(median age, 65 years; range, 37–83 years). All subjects
had tumors classified as T2 and T3 without lymph node
or distant metastases (AJCC/UICC stage I and II, Dukes
A and B). A retrospective study was performed on the
clinical outcome of these patients. All surviving patients
had been thoroughly informed about the study and gave
written consent for the investigation in accordance with
the ethical guidelines of our university. All patients were
operated on by the same surgeon (C.C.). This most likely
eliminated any surgeon-related prognostic factors that
could have interfered with survival analysis.20 Opera-
tions were defined as radical when there had been no
evidence of distant metastases or incomplete macro-
scopic clearance of the tumor and the pathologist re-
ported tumor-free margins of the specimen. Complete
circumferential excision of the mesorectum was per-
formed in all patients with extraperitoneal carcinoma
(middle and lower rectum); a distal clearance of at least
2 cm of healthy mucosa from the lower edge of the tumor
was provided in all the patients who had undergone
sphincter-saving operations. No patient received pre- or
postoperative radiotherapy or chemotherapy. The median
duration of follow-up for surviving patients was 67
months (range, 50–110 months).
Histopathological Staging
All surgical specimens were fixed in 10% formalin
solution and routinely processed for paraffin embedding.
We evaluated the following histopathological parameters
for each tumor specimen: tumor type, classified into
adenocarcinoma and mucinous carcinoma when more
than 50% of the tumor volume was composed of mucin;
tumor differentiation, classified as well differentiated,
moderately differentiated, and poorly differentiated, ac-
cording to the World Health Organization criteria21; the
depth of invasion of the tumors, classified as T2 (inva-
sion of the muscularis propria) or T3 (invasion into the
subserosa or into nonperitonealized perirectal tissues
through the muscularis propria) according to the AJCC/
UICC cancer staging system22; extramural venous inva-
sion, assessed according to the method described by
Talbot et al.23; the character of the invasive margin
(expanding or infiltrating) and lymphocytic infiltration
(conspicuous or little/absent), assessed according to cri-
teria defined by Jass et al.24 The median number of
lymph nodes recovered and examined in the surgical
specimens was 12 (range, 2–42).
Microvessel Immunohistochemical Staining
A monoclonal antibody against the endothelial antigen
CD31 was used to stain the microvessels. Four-microme-
ter-thick sections were cut from formalin-fixed and par-
affin-embedded tumor tissue blocks. They were mounted
on poly-L-lysine-coated slides, dewaxed in xylene, and
rehydrated through a graded series of ethanol. After
deparaffinization, the sections were treated with 3% hy-
drogen peroxide in methanol solution for 20 minutes to
block endogenous peroxidase activity. Sections were
pretreated with protease type XIV (Sigma Chemical Co.,
St Louis, MO) in phosphate-buffered saline for 7 minutes
at 37°C and then at 4°C for 5 minutes to quench enzy-
matic digestion. After incubating with normal rabbit
serum for 5 minutes at room temperature, the slides were
incubated with CD31 monoclonal antibody (JC 70™;
Dako, Milano, Italy), diluted 1/10, for 30 minutes at
room temperature: this was followed by three washes
with phosphate-buffered saline. The streptavidin-biotin
method was used, with diaminobenzidine tetrahydro-
chloride as the chromogen. Sections were rinsed in
deionized water, counterstained with Mayer’s hematox-
ylin, and then dehydrated and mounted with Permount™
(Fisher Scientific, Fair Lawn, NJ). For negative controls,
we used a nonspecific immunoglobulin G (normal rabbit
immunoglobulin G) instead of primary antibody.
Microvessel Counting
One section per tumor was analyzed. MVD was eval-
uated by the same pathologist (A.P.) and reviewed by
one observer (L.M.). Neither pathologist had any knowl-
edge of the clinical outcome. The entire tumor section
was first carefully scanned at low magnification (100)
to find the areas that showed the most intense neovascu-
larization (hot spots). These hot spots were identified as
areas with the highest density of brown stained CD31
cells. The microvessels that were included in the MVD
counts were only those that had been in the stroma
surrounded by malignant glands; the microvessels that
had been found within areas of granulation tissue, such
those near the surface of ulcerated tumors, were excluded
from MVD counts. Individual microvessels in the hot
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spots were then counted in a single 250 field. Any
immunoreactive endothelial cell or endothelial cell clus-
ter that was clearly separated from the adjacent mi-
crovessels was considered as a single countable vessel.
No vessel lumens or red blood cells were used to define
a microvessel. The occasionally found immunoreactive
lymphocytes, macrophages, and plasma cells were ex-
cluded on the basis of the staining pattern and cell
morphology. MVD in each tumor was expressed as the
microvessel count of the hot spot with the highest num-
ber of microvessels according to the methods proposed
by Weidner.10
Statistical Analysis
Correlation between the microvessel count in the hot
spot with the highest MVD and the microvessel count in
the hot spot with the second highest MVD within the
same tumor section was analyzed with Spearman’s rank
test. The relationships between MVD and the other clin-
icopathological variables were examined with the 2 test.
The relationship between clinicopathological variables
and survival was estimated with the Kaplan-Meier meth-
od.25 The Cox proportional hazards regression model26
was used to identify those clinicopathological factors
that independently influenced survival. For all the anal-
yses, Stata Statistical Software™ release 6.0 (Stata
Corp., College Station, TX) was used. A P value of .05
or less was considered significant.
RESULTS
Patient Outcome and Clinicopathological Variables
Thirty-five (41.7%) of the 84 patients had T2 tumors,
and 49 (58.3%) had T3 tumors. Seventy-eight tumors
(92.9%) were classified as adenocarcinomas and six
(7.1%) as mucinous carcinomas. Seventeen adenocarci-
nomas (21.8%) were well differentiated, and 61 (78.2%)
were moderately differentiated. No tumor was classified
as poorly differentiated. Tumor invasion of the extramu-
ral veins was present in 14 (16.7%) patients; it was
absent in 70 (83.3%). Forty-six (54.8%) tumors were
classified as having an expanding invasive margin and
38 (45.2%) as having an infiltrating one. Lymphocytic
infiltration was conspicuous in 16 patients (19.0%); it
was little or absent in 68 (81.0%).
In each tumor section, the microvessel count of the hot
spot with the highest MVD significantly correlated with
the microvessel count of the hot spot with second highest
vessel density (r  .74, P  .0001; Fig. 1). The median
MVD of all the patients was 45 (range, 18–153). This
cutoff was used to identify two groups of patients. Low
MVD (45) was found in 41 patients (48.8%), and high
MVD (45) was found in 43 (51.2%) patients. Figure
2A and B shows representative cases with low and high
MVD, respectively. A highly significant association was
FIG. 1. Microvessel counts in all 84 sections stained for CD31:
microvessel counts of vascular hot spots with the highest microvessel
density (MVD) correlated significantly with microvessel counts of
vascular hot spots with the second highest MVD (r  .74; P  .0001)
FIG. 2. CD31 immunostaining. Representative cases of tumor spec-
imens with a low vascular hot spot (arrow) (A) and a high vascular hot
spot (arrows) (B) (250).
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found between tumors with high MVD and those with
conspicuous lymphocytic infiltration (P  .001; Table
1). Figure 3 shows a representative tumor sample with
conspicuous lymphocytic infiltration and high MVD. No
significant association was found between MVD and the
other clinicopathological features.
Prognosis
Sixty-five of the 84 patients were alive at the time of
the last follow-up: none showed any evidence of the
disease. Nineteen patients had died of disease relapse.
Nine patients (10.7%) had distant metastases, six patients
(7.1%) had local recurrence, and four patients (4.7%) had
both distant metastases and local recurrence. The overall
rate of tumor relapse in our study was comparable to that
reported by other authors who did not perform pre- or
postoperative adjuvant therapy.27–29 In univariate analy-
sis, the depth of local invasion and the character of the
invasive margin were significantly related to survival
(Table 2). The 5-year survival rate of patients with T2
(Dukes A) tumors was 89.8%; it was 63.3% for those
patients with T3 tumors (Dukes B; P  .01). When
survival was compared with the character of the invasive
margin, the patients with expanding tumors had an
89.9% 5-year survival rate, whereas patients with infil-
trating tumors had a 57.0% 5-year survival rate (P 
.001). No significant association was found between
MVD and survival. The prognostic value of MVD and
the other clinicopathological variables was also exam-
ined by multivariate analysis with the Cox proportional
TABLE 2. Association of clinicopathological factors with








65 44 (52.4) 84.0
65 40 (47.6) 66.0 .07
Sex
Male 60 (71.4) 73.6
Female 24 (28.6) 82.3 .45
Histotype
Mucinous 6 (7.1) 80.7
Adenocarcinoma 78 (92.9) 75.6 .87
Tumor differentiation
Well differentiated 17 (21.8) 82.3
Moderately differentiated 61 (78.2) 73.8 .44
Depth of invasion
T2 35 (41.7) 91.2
T3 49 (58.3) 64.9 .01
Venous invasion
Absent 70 (83.3) 77.7
Present 14 (16.7) 67.1 .49
Character of invasive margin
Expanding 46 (54.8) 90.8
Infiltrating 38 (45.2) 58.5 .001
Conspicuous lymphocytic infiltration
Present 16 (19.0) 80.7
Absent 68 (81.0) 74.7 .60
Microvessel density
45 41 (48.8) 70.7
45 43 (51.2) 80.8 .20
TABLE 1. Relationships between clinicopathological
variables and microvessel density (MVD) in 84 patients with









65 21 (47.7) 23 (52.3)
65 20 (50.0) 20 (50.0) .83
Sex
Male 32 (45.3) 28 (46.7)
Female 9 (37.5) 15 (62.5) .18
Histotype
Mucinous 2 (33.3) 4 (66.7)
Adenocarcinoma 39 (50.0) 39 (50.0) .43
Tumor differentiation
Well differentiated 7 (41.2) 10 (58.8)
Moderately differentiated 32 (52.5) 29 (47.5) .41
Poorly differentiated 0 0
Depth of invasion
T2 16 (45.7) 19 (54.3)
T3 25 (51.0) 24 (48.9) .63
Venous invasion
Absent 33 (47.1) 37 (52.9)
Present 8 (57.1) 6 (42.9) .49
Character of invasive margin
Expanding 20 (43.5) 26 (56.5)
Infiltrating 21 (55.3) 17 (44.7) .28
Conspicuous lymphocytic
infiltration
Present 2 (12.5) 14 (87.5)
Absent 39 (57.4) 29 (42.6) .001
Tumor relapse
Absent 30 (46.2) 35 (53.8)
Present 11 (57.9) 8 (42.1) .36
FIG. 3. CD31 immunostaining. Representative case of tumor speci-
men with conspicuous tumoral lymphocytic infiltration and a high
vascular hot spot (arrow) (100).
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hazards model. Only the character of the invasive margin
emerged as an independent prognostic factor (Table 3).
DISCUSSION
The relationship between quantitative assessment of
angiogenesis, assessed as MVD, and prognosis has been
studied in many types of tumors, including colorectal
cancer.13–16 Most of these studies have shown that a high
density of microvessels is associated with short-term
survival and thus can be considered a marker of tumor
aggressiveness.
The need for new prognostic factors is particularly
urgent for LNN colorectal cancer patients. In fact, this
group of patients is still a broad category with respect to
clinical outcome. It is of critical importance that addi-
tional prognostic information be available to better iden-
tify those patients who are likely to experience tumor
relapse. As a consequence, they could receive the most
benefit from adjuvant therapy. There is as yet no con-
sensus regarding the prognostic value of MVD in early-
stage colorectal cancer. In two published studies on LNN
colon cancer,17,18 prognosis was significantly better in
the low-MVD patient groups than in those with high
MVD. These results were not confirmed when tumors of
the colon and of the rectum were analyzed together.
Banner et al.19 reported contrasting results: microvessel
counts in stage II colorectal cancer subjects were higher
in their long-term survival patient group than in their
short-term one. To our knowledge, this study is the first
to address the question of the prognostic importance of
angiogenesis in LNN rectal cancer. The purpose of this
study was to evaluate whether the predictive value of
MVD could compete successfully with the prognostic
importance of the well-known histopathological param-
eters in rectal cancer, such those used in the Dukes and
Jass colorectal cancer staging classifications. We found
that both the depth of local invasion and the character of
the invasive margin were significant predictors of sur-
vival in univariate analysis. However, only the character
of the invasive margin emerged as an independent prog-
nostic factor from multivariate analysis. Tumor type and
differentiation, venous invasion, lymphocytic infiltra-
tion, and MVD failed to show any relevance in predict-
ing survival.
We found a significant correlation between the degree
of lymphocytic infiltration and MVD: tumors with con-
spicuous lymphocytic infiltration were more frequent in
the high-MVD group than in the low-MVD one. Our data
are consistent with findings reported by Giatromanolaki
et al.30 They found a striking association between
CD31 lymphocyte infiltration and high vascular den-
sity. Moreover, they did not find any correlation between
microvessel count and prognosis in their Dukes B pa-
tients. A similar association was reported in patients with
non-small-cell lung carcinoma31 and in those with renal
tumors.32 These findings are not surprising. A number of
recent studies have demonstrated that the inflammatory
cell infiltrate significantly contributes to the angiogenic
process in malignant disease.33–35 As regards colorectal
cancer, it has been demonstrated that PD-ECGF is
mainly expressed by tumor-infiltrating macrophages and
lymphocytes. Thus, PD-ECGF is considered one of the
most important promoters of the angiogenic pathway
associated with the immune response against cancer.36,37
All these data, when taken together, may provide an
explanation for our results. Jass38 has demonstrated that
conspicuous lymphocytic infiltration is more frequently
associated with early-stage rectal tumors than with those
with lymph node or distant metastases. This infiltration
has been considered the expression of an effective cell-
mediated immune response against the tumor. The activ-
ity of the immune cells has also been associated with the
production of angiogenic promoters and, thus, with stim-
ulation of tumor vascularity.33–37 As a consequence, the
favorable prognostic effect of the host immunological
reaction to invading rectal carcinoma, i.e., the presence
of conspicuous lymphocytic infiltration, might interfere
TABLE 3. Survival analysis using multivariate Cox proportional hazards regression model
Prognostic factors Hazard ratio 95% Confidence interval P value
Age (65 y vs. 65 y) 1.94 0.714–5.319 .193
Sex (male vs. female) 1.45 0.443–4.750 .538
Histology (mucinous vs. adenocarcinoma) .94 0.114–7.853 .960
Differentiation (moderately vs. well) 1.11 0.302–4.084 .784
Depth of invasion (T3 vs. T2) 1.72 0.366–8.153 .489
Invasive margin (infiltrating vs. expanding) 5.39 1.245–23.345 .024
Lymphocytic infiltration (absent vs. present) 1.40 0.359–5.474 .626
Venous invasion (present vs. absent) .78 0.233–2.632 .693
MVD (low vs. high) .89 0.301–2.633 .834
MVD, microvessel density.
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with the negative effect of a large vascular surface area
within the tumor. The result would be a lack of any
significant prognostic significance regarding either
MVD or the degree of lymphocytic infiltration. This
hypothesis may explain our results in LNN rectal cancer
patients.
Failure of capacity of the degree of lymphocytic infil-
tration to be a significant prognostic factor has been the
experience of other investigators.39–41 This finding has
been explained by poor interobserver and intraobserver
reproducibility as regards this histopathological parame-
ter. However, none of the studies mentioned39–41 ever
noted or even suggested that there could be any associ-
ation between the immune response and the promotion of
the angiogenic process as an explanation for their results.
Another hypothesis that may explain our findings was
put forth by Giatromanolaki et al.30 They suggested the
presence of specific angiogenic profiles that may differ
substantially with regard to tumor relapse; i.e., the an-
giogenic pathway associated with the immune response
may not be associated with aggressive tumor behavior.
This hypothesis has been given further support by re-
cently reported data on a significant association between
the expression of PD-ECGF and a good prognosis in
colorectal cancer.37
It has been suggested42 that the discrepancy in results
regarding the prognostic value of microvessel count
might be related to some differences in methodology.
The choice of the endothelial antibodies for immunohis-
tochemical staining and the selection of the area for
microvessel quantification have been among the vari-
ables cited. In our study, a monoclonal antibody against
CD31 was used to highlight the endothelial cells, and the
microvessels were counted in the areas that showed the
highest degree of vessel density (hot spots), as suggested
by a recent international consensus on the methodology
and criteria of angiogenesis quantification.42 Another
issue that should be addressed is the possible heteroge-
neity of tumor vascularity within each histopathological
section. We found that the microvessel count of the hot
spot with the highest MVD significantly correlated with
the microvessel count of the hot spot with the second
highest MVD. This finding supports the hypothesis that
the degree of vascularization in different hot spots may
be similar within the same colorectal tumor section and
thus might represent a biological feature of a single
tumor, as previously suggested by Vermeulen et al.43
In conclusion, MVD does not seem to provide any
additional prognostic information when compared with
standard histopathological variables in patients with
LNN rectal cancer. The frequent presence of conspicu-
ous lymphocytic infiltration in early-stage rectal cancer
and the effective role of the immune cells in promoting
the angiogenic process may interfere with the effective-
ness of MVD in predicting the clinical outcome in this
group of patients.
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